Navigation Links
Generex Announces Patent Award for its Core Vaccine Technologies in Japan
Date:2/1/2012

WORCESTER, Mass. and TORONTO, Feb. 1, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that its wholly owned subsidiary, Antigen Express, Inc., has been awarded a Japanese Patent centering on its Ii-Key technology for the development of immunotherapeutic vaccines.  A number of products developed with this technology are currently in clinical development.  The patent helps to secure the novel Antigen Express vaccine technology platform in the international community.  International counterparts have been granted in Australia, China, and the United States.  The European counterpart has been allowed, and the Canadian application is pending.

(Photo:  http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b )

About AE37 and Ii-Key Hybrid Platform Technology

Antigen Express is a platform technology and product-based company developing proprietary vaccine formulations for large, unmet medical needs.  The Company's Ii-Key Hybrid technology platform entails the modification of fragments of antigens to increase their potency in stimulating critical members of the immune response, known as CD4+ T helper cells.  Incorporating the Ii-Key modification along with tumor-associated antigens can greatly enhance the immune system's ability to recognize and destroy cancer cells bearing any of the targeted antigens as well as increasing immunological memory.

The first product candidate utilizing the Company's novel Ii-Key Hybrid technology platform is a HER-2/neu Peptide Vaccine (AE37).  This "off-the-shelf" cancer immunotherapy product candidate is easier and less costly to produce than comparable cell-based approaches.  AE37 is derived from a peptide fragment of the human epidermal growth factor receptor 2 (HER2) oncoprotein, which is expressed in a variety of tumors including 75-
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
2. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
3. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
4. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
5. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
6. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
7. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
8. Generex Provides Additional Details for October 21st Live Video Webcast
9. Generex Announces $3.0 Million Capital Investment
10. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
11. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Israel , September 2, 2015 ... the intent of the National Institute of Allergy and Infectious ... (NIH) within the Department of Health and Human Services (HHS), ... in the United States in the ... universal flu vaccine candidate, Multimeric-001 (M-001), as a primer vaccine, ...
(Date:9/2/2015)... Whitehouse, NJ (PRWEB) , ... September 02, 2015 ... ... key Technical Services Staff members will be attending Pharma Ed Resources upcoming ... and respected group of industry leading speakers, this timely conference will provide Updates ...
(Date:9/2/2015)... ... September 02, 2015 , ... Genedata, a ... today unveiled Genedata Screener ® version 13.0 at ELRIG Drug Discovery 2015. ... market a rich set of new capabilities. Screener now supports High Throughput Flow ...
(Date:9/1/2015)... Sept. 1, 2015 The American Brain Tumor ... for its Discovery Research Grant program. LOIs are due ... noon CDT. Discovery Grants are one-year, $50,000 ... potential to change current diagnostic or treatment paradigms for ... encourage novel research at its earliest stages, in the ...
Breaking Biology Technology:BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2
... StemCyte Inc. today announced,that Chief Scientific Officer Ram ... on the StemCyte,s Indian joint venture at the TiEcon,2008 ... during the session on "Stem Cells - The Future,Promise ... May 17. His,presentation will include information about the development ...
... May 16 The landscape of scientific,publications strategy, ... of,transparency guidelines. Half of global publications groups are ... foresee a shift,to medical groups to increase clinical ... Practices, LLC., In a benchmarking study that ...
... Novasep have,extended their partnership to develop large scale ... systems and equipment,will meet the growing needs of ... instruments for gram to industrial,scale production of high ... is to combine Chromatide,s experience,in solid phase synthesis ...
Cached Biology Technology:StemCyte Chief Scientific Officer to Present Company Overview with Focus on Indian Joint Venture at TiEcon 2008 2Industry Executives Finding Value in Shift of Scientific Publications 2Chromatide and Novasep Have Extended Their Partnership to Develop Large Scale Solid Phase Peptide and Oligonucleotide Synthesis Technology. 2Chromatide and Novasep Have Extended Their Partnership to Develop Large Scale Solid Phase Peptide and Oligonucleotide Synthesis Technology. 3Chromatide and Novasep Have Extended Their Partnership to Develop Large Scale Solid Phase Peptide and Oligonucleotide Synthesis Technology. 4
(Date:8/20/2015)... , Aug. 20, 2015   Sensory, ... on improving the user experience and security of ... technologies, today announced that its TrulySecure™ ... authentication software to be FIDO Certified™. ... for compliance with the FIDO UAF (Universal Authentication ...
(Date:8/19/2015)...  VOXX International Corporation (Nasdaq: VOXX ) ... Definitive Agreement to purchase the assets, inclusive of ... EyeLock through an acquiring entity.  Upon consummation of ... in the acquiring entity. The closing of the ...  Expanding on its existing supply chain and distribution ...
(Date:8/18/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ... "Global Biometric Authentication & Identification Market: Focus On ... 2015-2020" report to their offering. ... market is expected to grow at an estimated ... generate over $25 billion (approximately) by 2020 as ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
... in some regions and increasing global demand for high ... water globally. This was the main conclusion of a ... Education. The special report follows a strategic workshop ... rules of international trade" held on 25th - 26th ...
... at the Genome Institute of Singapore (GIS) have, for ... comes with a guarantee on its reliability when reconstructing ... streamlined process for reconstructing and studying genomic sequences. ... of Computational and Mathematical Biology at the GIS, was ...
... fish have a greater capacity to cope with rising sea ... The discovery, by researchers at the ARC Centre of ... sheds a ray of hope amid the rising concern over ... levels of global warming expected to occur by the end ...
Cached Biology News:Experts call on governments, industries and the water and trade research communities 2Researchers at GIS develop systematic approach for accurate DNA sequence reconstruction 2When the heat's on, fish can cope 2When the heat's on, fish can cope 3